Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amur Minerals ( (GB:CRTX) ) has issued an update.
CRISM Therapeutics Corporation has been awarded a grant by Innovate UK to advance the pre-clinical development of its ChemoSeed technology for prostate cancer treatment. This project aims to develop a docetaxel-loaded implantable device that offers targeted chemotherapy delivery directly to the prostate, addressing the limitations of traditional treatments. The initiative, in collaboration with Ulster University, Queen’s University Belfast, and Axis Bio, seeks to establish a foundation for clinical trials and market introduction, potentially transforming prostate cancer therapy and tapping into a growing market projected to reach $22 billion by 2030.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based company specializing in innovative drug delivery technologies aimed at enhancing the clinical performance of cancer treatments for solid tumors. Their flagship product, ChemoSeed, is designed to deliver chemotherapy drugs directly to tumors, improving efficacy and reducing systemic side effects. The company is focused on localized delivery methods to address critical needs in cancer therapy, including prostate and brain tumors.
YTD Price Performance: -36.36%
Average Trading Volume: 22,687
Technical Sentiment Signal: Buy
Current Market Cap: £609.4K
For an in-depth examination of CRTX stock, go to TipRanks’ Stock Analysis page.